Leber's amaurosis treatment approved
In the USA, gene therapy was allowed to treat rare forms of vision loss
The FDA has approved an innovative gene therapy for the treatment of patients with a rare form of hereditary vision loss, according to the agency's website (FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss).
According to the statement, a therapy called Luxturna, developed by Spark Therapeutics, received approval.
"The FDA today approved Luxturna, a new gene therapy, for the treatment of children and adult patients with a hereditary form of vision loss that can lead to blindness. Luxturna is the first gene therapy approved in the USA, which is aimed at (treating – ed.) a disease caused by mutations in a certain gene," the report says.
"Today's approval marks another achievement in the field of gene therapy, both in how therapy works and in expanding the use of gene therapy beyond cancer treatment... this key moment reinforces the potential of this revolutionary approach in the treatment of a wide range of complex diseases," said Scott Gottlieb, a spokesman for the office.
Portal "Eternal youth" http://vechnayamolodost.ru